Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700020515

Trial Profile

Clinical Trials Insight: 700020515

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitimagene ceradenovec (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Ark Therapeutics
  • Most Recent Events

    • 09 Mar 2010 Ark Therapeutics has withdrawn its MAA, according to a company media release. The EMEA's Scientific Advisory Group on Oncology re-examined the filing and concluded that this trial did not provide sufficient evidence of a clincial benefit.
    • 21 Dec 2009 The EMEA's CHMP adopted a negative opinion regarding the MAA, according to an Ark media release. The Committee's negative opinion was based on possible differences between groups in treatment delays, which could have affected the primary endpoint.
    • 14 Oct 2009 Results will be presented at the American Society of Neuro-Oncology Conference in New Orleans on 22 October 2009, according to an Ark Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top